Caldera and Evommune secure China licensing agreements for autoimmune drug assets

Caldera and Evommune announced they have entered licensing agreements with Chinese partners to bring their autoimmune drug programs to the Chinese market.

The deals come as the biopharma sector is averaging roughly one China licensing transaction each week throughout 2026, underscoring the strategic importance of China for growth.

By securing rights to develop and commercialize these assets locally, both companies aim to tap into China’s large patient base and accelerate revenue potential, while Chinese partners gain access to novel therapies.